Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD

BACKGROUND: Varoglutamstat (formerly PQ912) is a small molecule that inhibits the activity of the glutaminyl cyclase to reduce the level of pyroglutamate-A-beta (pGluAB42). Recent studies confirm that pGluAB42 is a particular amyloid form that is highly synaptotoxic and plays a significant role in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Vijverberg, E. G. B., Axelsen, T. M., Bihlet, A. R., Henriksen, K., Weber, F., Fuchs, K., Harrison, J. E., Kühn-Wache, K., Alexandersen, P., Prins, N. D., Scheltens, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381483/
https://www.ncbi.nlm.nih.gov/pubmed/34425883
http://dx.doi.org/10.1186/s13195-021-00882-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381483/
https://www.ncbi.nlm.nih.gov/pubmed/34425883
http://dx.doi.org/10.1186/s13195-021-00882-9

Ejemplares similares